MyMD
  • Contact MyMD
  • About Us
    • Team
  • Pipeline
    • MYMD-1®
    • Supera-CBD
  • Research
    • Clinical Trials
  • Investors
  • News
    • MyMD News
    • Press Releases
    • Thought leadership
    • Perspectives
  • Subscribe
  • Contact MyMD

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 20, 2023 8:55am EDT

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Mar 08, 2023 8:30am EST

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Mar 02, 2023 8:30am EST

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Feb 28, 2023 8:30am EST

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Feb 21, 2023 8:45am EST

MyMD Announces $15 Million Offering with Existing Investors

Dec 06, 2022 8:00am EST

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Nov 17, 2022 8:00am EST

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Nov 14, 2022 8:00am EST

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Sep 20, 2022 8:00am EDT

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Aug 30, 2022 8:30am EDT

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Connect with MyMD Pharmaceuticals

Subscribe to stay up-to-date on new developments at MyMD.

Contact Us

MyMD

© 2023 MyMD Pharmaceuticals™. All Right Reserved

  • Privacy Policy
  • Terms & Conditions

This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition.

News & Resources

View a collection of articles, thought leadership content and industry news.

Subscribe to receive MyMD announcements
  • This field is for validation purposes and should be left unchanged.